Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Single-Arm Study of BeneFIX in Children <6 Years With Severe Hemophilia B
2014-004155-32Phase 3
- Sponsor
- Wyeth
- Start
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of coagulation factor ix recombinant in hemophilia B (HB), sponsored by Wyeth. Primary endpoints: Dose of Recombinant Human Factor IX (rFIX), Safety of rFIX and 2 more.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2014-004155-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004155-32.